• Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

  • VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock

  • VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock

  • VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting

  • VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update

  • VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update

  • Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers

  • Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies

  • VolitionRx Limited Releases Annual Corporate Brochure and Video

  • VolitionRx Limited to Present at Conferences in March 2020

  • VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update

  • VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update

  • Volition Unveils Its Epigenetic Toolbox

  • VolitionRx Announces Filing of Registration Statements

  • Volition Develops a New Improved Nu.Q™ Assay Format

  • VolitionRx Completes Acquisition of Octamer GmbH

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus